Ratings PureTech Health plc

Equities

PRTC

GB00BY2Z0H74

Market Closed - London S.E. Other stock markets 11:35:17 2024-05-10 am EDT			5-day change	1st Jan Change
222 ^GBX	-0.45%		+1.37%	+14.32%

May. 10	EARNINGS AND TRADING: Asiamet Resources declares special dividend	AN
May. 10	EARNINGS AND TRADING: Asiamet Resources declares special dividend	AN

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PURETECH HEALTH PLC	+14.32%	751M	B
MODERNA, INC.	+17.96%	44.96B	B-
LONZA GROUP AG	+48.77%	41.85B	A
IQVIA HOLDINGS INC.	+1.17%	42.65B	B
CELLTRION, INC.	-4.27%	29.04B	C
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B	B
BIO-TECHNE CORPORATION	+4.86%	12.75B	B+
MEDPACE HOLDINGS, INC.	+27.29%	12.06B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes